The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 12, 2008, Pages 1293-1299

  El Serag, H B ^a,b   Wieman, M ^a   Richardson, P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ADULT; ARTICLE; BARRETT ESOPHAGUS; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT DURATION; VETERAN;

ALGORITHMS; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43849092977     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03690.x     Document Type: Article

References (12)

1. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol 1997 92 : 27 31.
2. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997 92 : 1293 7.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 825 31.
4. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002 97 : 1888 95.
5. Sharma P. Barrett esophagus: will effective treatment prevent the risk of progression to esophageal adenocarcinoma? Am J Med 2004 117 (Suppl. 5A 79S 85S.
6. Basu KK, Bale R, West KP, de Caestecker JS. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy. Eur J Gastroenterol Hepatol 2002 14 : 1187 92.
7. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000 14 : 597 602.
8. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004 99 : 1877 83.
9. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004 180 : 387 91.
10. Sales MM, Cunningham FE, Glassman PA, Valentino MA, Good CB. Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003. Am J Manag Care 2005 11 : 104 12.
11. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol 1995 141 : 242 50.
12. Morgan R. Individual-level Factors Affecting Enrollment in Medicare + Choice Plans and Use of VA Medical Care by Medicare Enrolled White, African American and Hispanic Veterans. Technical Report. Included in the Final Project Report for the study, Medicare HMO Enrollment and VA Use by Minority and Low-Income Veterans (VA HSR&D IIR 20-052) 2004 personal communication Y, Hendricks A, Zhang S, Kazis LE. VHA enrollees' health care coverage and use of care. Med Care Res Rev 2003 60 : 253 67.